Intussusception Risk after Rotavirus Vaccination in U.S. Infants

Project Title Intussusception Risk after Rotavirus Vaccination in U.S. Infants
Date
Thursday, February 6, 2014
Location
Description

This article describes the findings of a study conducted to evaluate the risk of intussusception associated with two Rotavirus vaccines, Rotateq (RV5) and Rotarix (RV1), in infants 5 to 30.9 weeks of age in the United States. 

Medical Product
RotaTeq
Rotarix
rotavirus vaccine
Health Outcome
intussusception
Population / Cohort
All infants 5 to 30.9 weeks of age
Time Period
2004–2011
Corresponding Author

W. K. Yih, Department of Population Medicine, Harvard Pilgrim Healthcare Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, U.S.A. E-Mail: katherine_yih@harvardpilgrim.org

Authors

W. Katherine Yih PhD, MPH; Tracy A. Lieu MD, MPH; Martin Kulldorff PhD; David Martin MD, MPH; Cheryl McMahill-Walraven PhD, MSW; Richard Platt MD, MSc; Nandini Selvam PhD, MPH; Mano Selvan PhD; Grace M. Lee MD, MPH; Michael Nguyen MD

Data Sources
Mini-Sentinel Distributed Database (MSDD)
Related Links